SPB Git

spb/anomaly-atlas Public License

Systematic discovery & rigorous validation of statistical anomalies in open HF market data (hfmarketdata.io) — pre-registered, artifact-null-driven, fully reproducible. Live atlas: www.anomaly-atlas.io

Python 61.4% JavaScript 28.7% CSS 8.6% Shell 0.7% Makefile 0.5%

# project: anomaly-atlas document: expG_cost_frontier/analysis author: Simon-Pierre Boucher contact: contact@spboucher.ai data_source: hfmarketdata.io created: 2026-08-12 modified: 2026-08-12 status: reviewed

# Analysis — expG_cost_frontier

Run: results/expG_cost_frontier/20260812T072128Z/results.json (pool rebuilt mechanically from committed expC/expD/expF outputs — no hand-picking; cost model and κ sweep pre-declared; cache-served).

# The frontier

κ (× half-spread paid per trade) survivors / 31
0 (gross) 31
0.1 3 (AXDX 30min, CKX 1day, HTD 5min — all sparse names)
0.25 1 (CKX 1day, κ* = 0.28)
0.5 0
1.0 0

Median breakeven κ* = 0.0114: the median double-filtered rule captures ~1 % of one half-spread per trade. The intraday reversion cells sit at κ* 0.004–0.04; the 2014-2015 lead-lag residuals at 0.003–0.03; ES→SPY at 0.0028 (identical across all three splices). Zero intraday rules survive κ = 1 — the pre-registered falsification clause did not trigger.

# Reading

  1. The three-layer doctrine closes. expF showed statistical correction cannot detect mechanism; expG shows the mechanism's price: the gross survivors were harvesting exactly the thing they would have to pay. Charter Q5 answered on this pool: the cost frontier sits an order of magnitude below the most optimistic execution assumptions (Frazzini-style κ ≈ 0.1–0.25).
  2. The lone κ=0.25 survivor is the skeptic's case study. CKX (ultra sparse; wide, noisy EDGE spread; daily contrarian) has the classic profile of estimation artifact rather than economics. It is NOT discarded by hand — it goes to expH's validation split carrying the skeptical prior, which is what the protocol is for.

# Hand-off

expH evaluates on the untouched validation split: (i) CKX 1day (the lone cost survivor), (ii) the daily 2008-2015 reversal family (gross, cost-marginal — evaluated for the decay/negative record), and (iii) the NEGATIVE finding itself ("nothing intraday survives costs") — which, if it replicates out-of-sample, becomes the atlas's first confidence-labeled entries (charter result-types C and E).